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Abstract It is well-known that probiotics have a number of
beneficial health effects in humans and animals, including
the reduction of symptoms in lactose intolerance and en-
hancement of the bioavailability of nutrients. Probiotics
have showed to possess antimutagenic, anticarcinogenic
and hypocholesterolemic properties. Further, they were also
observed to have antagonistic actions against intestinal and
food-borne pathogens, to decrease the prevalence of aller-
gies in susceptible individuals and to have immunomodula-
tory effects. Typically, the bacteria colonise the intestinal
tract first and then reinforce the host defence systems by
inducing a generalised mucosal immune response, balanced
T-helper cell response, self-limited inflammatory response
and secretion of polymeric IgA. Scientific reports showed
that the Taiwan native lactic acid bacterium from newborn
infant faeces identified as Lactobacillus paracasei subsp.
paracasei NTU 101 and its fermented products proved to be
effective for the management of blood cholesterol and pres-
sure, prevention of gastric mucosal lesion development,
immunomodulation and alleviation of allergies, anti-
osteoporosis and inhibition the fat tissue accumulation. This
review article describes that the beneficial effects of this
Lactobacillus strains and derivative products may be suitable
for human and animals.
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Introduction
Lactic acid bacteria (LAB) collectively represent a major
part of the commensal microbial flora of the human gastro-
intestinal tract and are frequently used as probiotics either
singly or in combination for fermentation of food products.
Lactobacillus, Streptococcus and Bifidobacterium are the
most commonly used (Fooks et al. 1999). Probiotics are
available in different forms, including foods in a fermented
state, and in the form of pills mainly as capsules or micro-
encapsulated forms. By considering the many types of po-
tential fermentation substrates and conditions, LAB strains
may be regarded as functional performance bacteria and are
expected to be used in the development of new food-based
probiotics in the future. Probiotics not only acts on the large
intestine by affecting the intestinal flora but also affects
other organs by modulating the immunological parameters
and intestinal permeability and by producing bioactive or
regulatory metabolites (de Vrese and Schrezenmeir 2008).
Dietary supplementation with live beneficial bacteria pro-
motes health effects and reduces the risk of various diseases
(Ahrne et al. 1998).
The probiotic market in the USA was estimated to be
close to $1.5 billion in 2010. Total production of sour cream
and yogurt was 5.4 billion lb at 116 processing plants in the
USA in 2010 (USDA 2011). Increased production has been
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observed among the dairy-type and non-dairy probiotic
foods, such as fermented meats as well as vegetable and
fruit juices. Considering the wide range of fermentable sub-
strates that can be used to obtain different products under
different conditions by LAB strains, it is expected that
development of new food-based probiotics will continue in
the future (Holzapfel 2006).
Lactobacilli are gram-positive, non-spore forming, rod-
shaped, anaerobic bacteria. Many Lactobacillus strains are
used in food fermentation and are typically used in the dairy
industry to produce cheese, yogurt and other fermented milk
products (Schmid et al. 2006). They have complex nutri-
tional requirements and are found in a variety of habitats,
such as human and animal mucosal membranes, on material
of plant origin and in sewage as well as in fermented milk
products and spoiling food (de Vrese and Schrezenmeir
2008). They are important for enhancing immunity, mainte-
nance of the intestinal microbial balance and prevention of
gastrointestinal infection.
A lactic acid bacterium isolated from native newborn
infant faeces in Taiwan was characterised, and the isolates
were identified as Lactobacillus paracasei subsp. paracasei
NTU 101. This strain showed good survival at low pH,
tolerance against high bile concentrations and the ability to
reduce serum cholesterol in vitro (Pan et al. 2002). Further-
more, a milk–soymilk mixture was fermented by L. para-
casei subsp. paracasei NTU 101 and Bifidobacterium
longum BCRC11847. Based on the sensory evaluation
results, supplementation with 5% Lycium chinense Miller
juice was found to improve the overall acceptability of the
fermented milk–soymilk mixture. The pH and titratable
acidity in the fermented beverage was slightly altered, and
the quantities of cells of L. paracasei subsp. paracasei
NTU101 and B. longum BCRC11847 were maintained at
1.2×109 and 6.3×108 CFU/mL after 14 days of storage (Lin
et al. 2004). Many studies have also proved that the bene-
ficial effects of L. paracasei subsp. paracasei NTU 101 and
its fermented foods were clearly well defined. This article is
summarised and compared with different effects among
lactic acid bacteria strains.
Hypocholesterolemic effect
Hypercholesterolemia increases the risk of cardiovascular
diseases (CVDs) such as atherosclerosis, coronary heart
disease and stroke. An estimated 6.15 million people died
from CVDs in 2008. This represents 10.8% of all global
deaths (WHO 2011). Low levels of high-density lipoprotein
cholesterol, high levels of low-density lipoprotein cholester-
ol (LDL-C) and oxidation of LDL are major risk factors and
initiators of atherosclerosis. Xie et al. (2011) found that
Sprague–Dawley rats fed a high-cholesterol diet experienced
reduced levels of serum cholesterol, LDL-C and triglyceride
(TG) after supplementation with Lactobacillus plantarum
9-41-A and Lactobacillus fermentum M1-16. These two
strains also improved the intestinal microbial balance and
the hypocholesterolemic effect. Wistar albino rats were fed
20% fresh or oxidised soybean oil supplemented with 5%
lyophilised culture or fermented milk prepared using Lacto-
bacillus casei subsp. casei for a period of 90 days (Kapila
and Sinha 2006). The plasma cholesterol levels and thio-
barbituric acid reactive substances (TBARS) in the LDL
fraction were lower in the group that was fed fermented
milk and lyophilised culture than the control group that was
fed skim milk.
In an earlier study, Syrian hamsters were fed a high-
cholesterol diet (5 g/kg diet) to induce hypercholesterol-
emia. Milk fermented by L. paracasei subsp. paracasei
NTU 101, L. plantarum NTU 102 and Lactobacillus acid-
ophilus BCRC 17010 was fed for 8 weeks. The levels of
serum and liver total cholesterol were also significantly
reduced by 23.5–30.1% and 13.4–17.7%, respectively.
These results showed that the hypocholesterolemic effect
of local Lactobacillus strains may be attributed to their
ability to lower serum and liver total cholesterol levels (Chiu
et al. 2006).
In addition, mixtures of milk–soymilk and milk–soymilk
supplemented with Momordica charantia were fermented
by lactic acid bacteria, and the effect on atherosclerosis in
hyperlipidemic hamsters was investigated (Tsai et al. 2009).
The hamsters that were fed L. paracasei subsp. paracasei
NTU 101 fermented milk–soymilk with and without M.
charantia experienced significantly decreased serum cho-
lesterol levels. Furthermore, atherosclerotic plaques in the
aorta were decreased by 69.0% relative to the group of
hamsters that were fed a high-cholesterol diet (H) (Fig. 1).
It was concluded that the anti-atherosclerotic activity of
NTU 101 fermented milk–soymilk is due to an increase in
the total antioxidant status activity of the blood and decrease
in the quantity of TBARS.
In high-cholesterol diet model, levels of cholesterol and
TBARS were elevated in rats or hamsters, while feeding
with the lactobacilli strains or fermented milks was effective
in reducing serum cholesterol, LDL-C and TG concentra-
tions. The mechanisms of lactic acid bacteria in altering the
serum cholesterol from these above mentioned results may
propose by directly absorbing and assimilation cholesterol
into the cell membrane (Noh et al. 1997) and decreasing
HMG-CoA reductase activity and cholesterol micelle for-
mation in vivo by metabolites of lactic acid bacteria like
short chain fatty acids (Fukushima and Nakano 1996). We
could suppose that L. paracasei subsp. paracasei NTU 101-
fermented milk–soymilk is effective in preventing and
retarding hyperlipidemia-induced oxidative stress and
atherosclerosis.
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Antihypertensive effect
Hypertension is another risk factor for CVDs. Angiotensin-
converting enzyme (ACE; EC 3.4.15.1) mediates blood
plasma, interstitial fluid volume and arterial vasoconstric-
tion in the body’s renin–angiotensin system (Imig 2004).
ACE inhibitors have beneficial effects in hypertension by
inhibition of the production of the vasoconstrictor angioten-
sin II and degradation of the vasodilator bradykinin (Seppo
et al. 2003).
LAB-fermented products may prevent hypertension via
substances such as γ-aminobutyric acid (GABA) and
Fig. 1 Effect of milk–soymilk
and fermented milk–soymilk on
atherosclerotic plaque in the
thoracic aorta of hyperlipidemic
hamsters. Top atherosclerotic
plaque presented as the red dye
in the graph. Bottom Proportion
of the area of atherosclerotic
plaque in the aorta. The whole
surface area of thoracic aorta
was stained by Sudan IV and
photographed using digital
camera. The aortic surface area
and its stained plaque area (red
dye) were selected and
quantitated by the Posterize
program of Photoshop 7.0
software (Adobe Systems
Incorporation, San Jose, CA,
USA). The selected pixel of
plaque area and whole aorta was
used to calculate the percent area
of the aortic plaque. N normal
diet (0% cholesterol), H
high-cholesterol diet, HP
probucol and high-cholesterol
diet, HS milk–soymilk and
high-cholesterol diet, HSF-101
milk–soymilk fermented by L.
paracasei subsp. paracasei
NTU 101 and high-cholesterol
diet, HSF-102 milk–soymilk
fermented by L. plantarum NTU
102 and high-cholesterol diet,
HM milk–soymilk supplement
with M. charantia and
high-cholesterol diet, HMF-101
milk–soymilk supplement with
M. charantia fermented by L.
paracasei subsp. paracasei
NTU 101 and high-cholesterol
diet, HMF-102 milk–soymilk
supplement with M. charantia
fermented by L. plantarum NTU
102 and high-cholesterol diet.
Data are presented as mean±SD
(n08), and numbers with a
different letter were significantly
different (p<0.05) from each
other (Tsai et al. 2009)
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angiotensin I-converting enzyme inhibitors (ACEIs). In
2002, Fuglsang et al. (2002) reported that feeding of milk
fermented with Lactobacillus helveticus CHCC637 and
CHCC641 to rats produces inhibition of angiotensin II con-
version, a drop in blood pressure and changes in heart rate.
Milk fermented with L. helveticus strains can produce ACEI
biogenic tripeptides like Val-Pro-Pro and Ile-Pro-Pro as
antihypertensive ingredients in spontaneously hypertensive
rats (SHR) (Yamamoto et al. 1999; Takano 2002; Seppo
et al. 2003) and hypertensive subjects (Hata et al. 1996;
Jauhiainen et al. 2010).
It was previously found that milk fermented with L.
paracasei subsp. paracasei NTU 101 (101FM) has ACEI
activity (85 mU/mL). This study aimed to investigate the
antihypertensive effects of 101FM orally administered to
SHRs. Eight hours after a single oral administration or after
8 weeks of weekly (chronic) administration, 101FM caused a
significant decrease in systolic and diastolic blood pressure in
the SHRs (Fig. 2). Microscopic examination of aortic tissue
demonstrated that 101FM reduces the disorganization of the
media layer (Fig. 3). These findings suggest that orally
administered 101FM has antihypertensive effects, possibly
via ACEI activity, in SHRs (Liu et al. 2011b).
All these results recommended that milk fermented by
lactic acid bacteria could enhance the content of bioactive
peptides (Yamamoto et al. 1999; Takano 2002; Seppo et al.
2003; Hata et al. 1996; Jauhiainen et al. 2010; Liu et al.
2011b) or aglycone isoflavones (Yeo and Liong 2010) to
reduce the blood pressure in animal model. The mechanism of
antihypertensive effects from milk peptides is mainly focused
on the inhibition of angiotensin-converting enzyme. However,
milk peptides may also have special mechanisms to lower
blood pressure by opioid-like activities, mineral-binding and
antithrombotic properties (Jauhiainen and Korpela 2007).
Fig. 2 Effect of administration of 101FM product on a SBP and b
DBP by a single oral and c SBP and d DBP by chronic feeding in SHR.
One group of the SHRs was fed a normal diet without the administra-
tion of test materials (control group, white circle). The other SHRs
were administered a 1-fold dose of Calpis (15 mL/kg/day including
2,380 mU of ACEI activity) (Calpis group, white square), a 0.5-fold
dose of 101FM (14 mL/kg BW/day including 1,190 mU of ACEI
activity) (101FM-0.5× group, black circle), a 1-fold dose of 101FM
(28 mL/kg BW/day including 2,380 mU of ACEI activity) (101FM-1×
group, black square) and a 2-fold dose of 101FM (56 mL/kg BW/day
including 4,760 mU of ACEI activity) (101FM-2× group, black trian-
gle). *p<0.05, p estimated by one-way ANOVA and versus the control
group (n08) (Liu et al. 2011b)
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Beneficial effects on immunomodulating activity
Recently, immune-mediated and gut-related health problems
have been recognised as global major progressive diseases.
Many rigorous studies have suggested that emerging nutri-
tional strategies including probiotics diets may be able to
reduce these host-related immune diseases and modulate the
intestinal microbiota. The main effects of probiotics on the
immune system in different life stages in humans have been
extensively been studied and targeted for these specific age
groups (Romeo et al. 2010). Probiotic bacteria induce mul-
tiple effects on the host by changing the intestinal luminal
environment, epithelial and mucosal barrier function and the
mucosal immune system. Numerous cell types are involved
in these responses, including the epithelial cells, dendritic
cells (DC), monocytes/macrophages, B cells, T cells and NK
cells (Ng et al. 2009). In murine models, several strains of
lactobacilli enhance both the innate and adaptive immune
response through induction of dendritic cell maturation and
further stimulate the lymphocytes to release pro-
inflammatory cytokines, including tumour necrosis factor-
alpha (TNF-α), interferon-gamma (IFN-γ) and interleukin-12
(IL-12) (Perdigon et al. 1999).
The possible time-dependent role of LAB in immunomo-
dulation was investigated in BALB/c mice receiving a daily
diet, including L. paracasei subsp. paracasei NTU 101
(108 CFU/day) for 3, 6 and 9 weeks and following feeding
with Lactobacillus-free food for a further 7 days (Tsai et al.
2008). The antigen-presenting ability of DC and the expres-
sion of natural killer group-2 D molecules capable of trig-
gering natural killer cell-mediated cytotoxicity by feeding
NTU 101 were found to be upregulated. Lymphocyte pro-
liferation and antibody production were also significantly
increased in mice after this treatment. Innate and adaptive
immunity remained constant even after the most protracted
feeding time. This indicates the time dependence of the
bacterial-mediated enhanced immunity (Tsai et al. 2008).
After feeding Lactobacillus, the percentages of CD4+ T cells
in both Peyer’s patches and the spleen were significantly
increased (Tsai et al. 2010a). The data also showed that
Peyer’s patch-derived immunomodulation induced higher
levels of intestinal IgA+-producing cells in the lamina prop-
ria. Feeding Lactobacillus also induced stronger CD4+ T
cell–dendritic cell interactions, enhanced CD4+ T cell and B
cell proliferation and increased mRNA expression levels of
IL-1β, IL-10, IL-12, IFN-γ and TNF-α in Peyer’s patches
(Tsai et al. 2010a). It was also reported that intestinal DC
could selectively induce IgA from the interactions with B cells
and protect against the penetration of gut microorganisms in
mucosal (Macpherson and Uhr 2004).
Fig. 3 Heart appearance and microscopic examination (×200 and ×400)
of aorta biopsy on experimental SHRs: a control group, b Calpis group, c
GABA group, d 101FM-0.5× group, e 101FM-1× group, f 101FM-2×
group, g 102FM-0.5× group, h 102FM-1× group, i 102FM-5× group
(the arrow points out the location of difference) (Liu et al. 2011b)
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Chiang et al. (2011b) have reported immunomodulation
effects of dead lactobacilli, whole cells and gastrointestinal
enzymatic hydrolysates of supernatants and precipitates from
L. paracasei subsp. paracasei NTU 101 on RAW264.7
macrophages and splenocytes. All of the hydrolysates and
whole cells from NTU 101 were observed to induce lower
levels of pro-inflammatory cytokines (IL-1β and IL-6) than
LPS. The supernatant of NTU 101 was found to activate the
cell division of RAW 264.7 macrophage from G0/G1 to the
S phase and to facilitate the advance to the G2/M phase as
well as increase the amount of IFN-γ in splenocytes, relative
to the NTU 101 precipitates. This indicates that hydrolysates
of NTU 101 induce the proliferation of macrophages and
splenocytes and promote the release of IL-10 and IL-12
cytokines to modulate the innate and adaptive immune
systems and inflammatory responses.
Polysaccharides are broadly used in the food industry as
gelling, thickening, stabilizing and emulsifying agents. Cer-
tain probiotics such as LAB also produce exopolysacchar-
ides that stimulate macrophage production of cytokines.
Liu et al. (2011a) have characterised the effects of exopo-
lysaccharides of L. paracasei subsp. paracasei NTU 101
exopolysaccharides (101EP) on antioxidant activity and
immunomodulation in vitro. Cytokine production (including
IL-6, TNF-α and IL-1β) was found to be induced by 101EP
in Raw 264.7 cells in a dose-dependent manner. This also
demonstrates the potential antioxidant properties (1,1-
diphenyl-2-picrylhydrazyl radical scavenging activity,
chelating of ferrous ions, inhibition of linoleic acid per-
oxidation and reducing power) of 101EP in vitro (Liu et al.
2011a).
The health-promoting effects of probiotic strains or relat-
ed fermented products are approved not only from them-
selves but also from their metabolites. According to these
results of the immunomodulating potential, L. paracasei
subsp. paracasei NTU 101 could enhance the lymphocyte
proliferation and antibody production as well as promote the
release of cytokines in intestinal tract by intact cells, hydro-
lysates or metabolites.
Prevention or alleviation of allergies and atopic diseases
Allergies are caused by an immune reaction that is dispro-
portionate to the antigenic stimuli. A major proportion of the
world population suffers from various types of allergies, and
the incidence of allergies is on the rise (Ouwehand 2007).
Pollen and food allergies and atopic dermatitis are classified
as IgE-mediated allergic diseases. These diseases are major
public health problems in many countries and are associated
with elevated levels of antigen-specific IgE antibodies
caused by improperly self-possessed T-helper (Th) type 2
responses (Yoshida et al. 2011).
Many types of LAB products, including dead or living
bacterial cells and fermented foods, have been investigated
for their anti-allergic effects in a murine model. Fujiwara et
al. (2004) showed that orally administered L. paracasei
KW3110 in a mouse allergy model directs the Th1/Th2
balance toward Th1 through the maturation of antigen-
presenting cells and inhibition of serum IgE elevation.
Sashihara et al. (2006) revealed that certain strains of heat-
killed L. plantarum and Lactobacillus gasseri had a higher
stimulatory activity for IL-12 production than the other
lactobacilli tested. These species were also found to reduce
the serum antigen-specific IgE levels in ovalbumin-
sensitised BALB/c mice. Enomoto et al. (2009) showed that
oral administration of L. plantarum NRIC0380 inhibits
antigen-specific IgE production and enhances the Th1 re-
sponse. In addition, orally administered heat-killed Lacto-
bacillus pentosus strain S-PT84 has been shown to lower
serum IgE levels, to suppress the active cutaneous anaphy-
laxis reaction and splenic IL-4 production and to upregulate
IL-10 production in OVA-immunised mice (Nonaka et al.
2008).
It has also been shown that the allergic response may be
induced by intraperitoneal injection or by oral or nasal
administration of OVA in mice (Bae et al. 2007; Kim et al.
2008a; Medeiros et al. 2008; Hougee et al. 2010; Tobita et
al. 2010a, b). In a previous study, 3-month-old male and
female BALB/c mice were divided into two groups: a pre-
sensitised group and a post-sensitised group. Levels of
cytokines (IFN-γ, IL-4, IL-10 and IL-12), serum antibodies
and subpopulations of lymphocytes were determined
(Chiang 2011). The results indicate that pre-sensitised
BALB/c mice have a higher level of allergy-related anti-
bodies in the serum and an equal amount of cytokines
derived from splenocytes in all groups. The oral adminis-
tration of lactobacilli was found to reduce only the total IgE
content in mice. For the post-sensitised model, the mice
were fed lactobacilli before induction of the allergic re-
sponse. As expected, the OVA-specific antibody levels were
low after the first week. At the end of the test, orally
administered L. paracasei subsp. paracasei NTU 101
showed an anti-allergic effect that arises as a result of a
reduction in OVA-specific IgE levels, an increase in Th1-
type cytokine IFN-γ levels and an increase in the IFN-γ/IL4
ratio. This treatment also induces lymphoproliferation activ-
ity as evidenced by the increase in the number of total T cell,
T helper and T cytotoxic cells in the spleen. L. casei strain
Shirota inhibited serum OVA-specific IgE and IgG1
responses and also skewed the pattern of cytokine secretion
by splenocytes (Shida et al. 2002). Intragastric administra-
tion of these lactobacilli strains to mice would affect the
cytokine Th1/Th2 balance towards non-allergic Th1 path-
way. It also reduced the allergy-related antibodies in serum
and induced the lymphocytes proliferation. These results
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indicate that the lactobacilli strains represent a potential
application in therapy of allergic diseases.
Prevention of pathogen infection and modification
of the intestinal microflora
The mechanism of involvement of probiotics in intestinal
homeostasis has been investigated. Targets of probiotics
have been found to be involved in the regulation of fluid
movement, lactose digestion/absorption, improvement of
the epithelial barrier function and increases in secretion of
IgA (Ménard and Heyman 2006). Effects of probiotic Lac-
tobacillus on the intestinal microflora and fermentation in-
clude inhibition of adherence and growth of pathogens and
harmful bacteria by secretion of lactate and short chain fatty
acids to decrease the luminal pH and stimulation of the
colonic blood flow and epithelial cell growth (Ohashi and
Ushida 2009).
Tsai et al. (2008) investigated the correlation of intestinal
microflora with immunity induced by L. paracasei subsp.
paracasei NTU 101. This correlation was determined by
measuring the content of probiotics and harmful microorgan-
isms. The results indicated alterations in intestinal microflora,
with increased numbers of bifidobacteria and lactobacilli and
decreased numbers of Clostridium perfringens after feeding
with L. paracasei subsp. paracasei NTU 101. It is possible
that persistent activation of immunity might be induced by
intestinal probiotics (Tsai et al. 2008). Probiotics are also
used as remedies for different types of intestinal infection
diseases, such as traveller’s diarrhoea caused by enterotoxi-
genic Escherichia coli (Caridi 2002; Ishida-Fujii et al. 2004;
Sun et al. 2010), irritable bowel syndrome (Søndergaard et
al. 2011) and enteric virus (Maragkoudakis et al. 2010). The
barrier effect of intestinal bacteria against the challenge of
pathogens is considered as its protective function.
E. coli O157:H7 is a highly infectious pathogen that
causes food-borne illnesses (Karch et al. 2005). Infection
often leads to haemorrhagic diarrhoea and kidney failure in
young children and elderly individuals. In a previous study,
the immunomodulating activity of L. paracasei subsp. para-
casei NTU 101 was investigated in enterohaemorrhagic E.
coli O157:H7-infected BALB/c mice (Tsai et al. 2010b).
Mice were fed L. paracasei subsp. paracasei NTU 101
(108 CFU/day) for 7 days, before and after the challenge
with E. coli O157:H7. Feeding of Lactobacillus for 7 days
resulted in upregulation of dendritic cells, helper T cell
activation and antibody production in post- and pre-treated
mice, relative to untreated mice in the E. coli O157:H7-
infected group. Moreover, Lactobacillus can decrease the
expression of Toll-like receptors on macrophages and proin-
flammatory cytokines and chemokines in the post- or pre-
fed mice infected with E. coli O157:H7. These findings
suggest that L. paracasei subsp. paracasei NTU 101 might
prevent human E. coli O157:H7 infections (Tsai et al.
2010b).
Common bacterial pathogens that cause gastrointestinal
infection diarrhoea include Campylobacter jejuni, Salmo-
nella and Shigella species, E. coli O157:H7 and Helico-
bacter pylori (Castillo et al. 2011; Ivanova et al. 2010;
Moran 2010; Tsai et al. 2010b). Conventional treatment of
bacterial infection is treated with antibiotics. To reduce the
adverse effects of antibiotic therapy, continuous administra-
tion of lactobacilli probiotics may be a useful tool to protect
against the pathogen infection. The protective mechanisms
of probiotics from these studies are mainly proposed from
modulating the inflammatory response against the entero-
pathogen in the gut.
Preventive effect on gastric mucosal lesions
Characteristics of ethanol-induced gastric mucosal injury
include reductions in gastric mucus, motility, transmucosal
potential difference, prostaglandin levels and gastric muco-
sal blood flow and increases in free radical generation, acid
back diffusion, histamine levels, 5-hydroxytryptamine re-
lease, cation efflux, leukotriene production, ischemia and
gastric vascular permeability (Glavin and Szabo 1992).
Many reports suggest that LAB and their fermented
products have protective effects against mucosal injury in
the stomach. Yogurt-containing L. gasseri OLL2716 (LG21
yogurt), which can compete with H. pylori in the gastric
mucus layer, resulting in decreased colonisation of the or-
ganism (Fujimura et al. 2006), has been shown to be effec-
tive in improving H. pylori-induced gastric mucosal
inflammation in humans (Sakamoto et al. 2001). In oral
administration of L. casei strain Shirota in H. pylori SS1-
infected mice, levels of H. pylori colonisation were signif-
icant reduction in the antrum and body mucosa. It also
observed that the associated chronic and active gastric mu-
cosal inflammation was decline (Sgouras et al. 2004).
Uchida and Kurakazu (2004) reported that the ingestion
of LG21 yogurt significantly and dose-dependently inhibits
the formation of acute gastric lesions caused by 0.6 M HCl in
rats. LG21 was also observed to increase the rate of prosta-
glandin E2 (PGE2) generation in the gastric mucosa, which
leads to prevention of gastric ulcers. Lactobacillus rhamno-
sus GG has also been reported to enhance gastric healing by
activation of epidermal growth factor receptor and upregu-
lation of expression of ornithine decarboxylase, B cell lym-
phoma 2 and vascular endothelial growth factor in ulcerated
tissues (Lam et al. 2007a). L. rhamnosus GG has also been
reported to stimulate mucus secretion and to increase trans-
mucosal resistance in the gastric mucosa (Lam et al. 2007b).
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In a previous study, L. paracasei subsp. paracasei NTU
101 and L. plantarum NTU 102 were used as starter to
ferment soy–skim milk. The influence of LAB-fermented
soy–skim milk on mucosal integrity in a gastric mucosal
lesion rat model was investigated (Liu et al. 2009). Pylorus
ligation with acidified ethanol treatment was used as a
gastric lesion animal model. Results showed that LAB-
fermented soy–skim milk could significantly reduce the
lipid peroxides of gastric mucosa and serum and the gastric
lesion index (Fig. 4 and Table 1). Dose-dependent inhibition
of acute gastric lesions was observed for the NTU 101
(109 CFU/day, 101-9 group) with significant differences.
The high dose of fermented soy–skim milk was also found
to enhance superoxide dismutase activity and PGE2 synthe-
sis. Rats fed commercial yogurt and soy–skim milk fer-
mented by NTU 101 (101-9) had normal mucosal
structure, which was significantly different from the
mucosal structure of the rats that were fed water or non-
fermented soy–skim milk. This normal mucosal structure is
expected to protect the rats against gastric injury.
From these results mentioned above, lactobacilli strains
may possess the defence against the injuries caused from H.
pylori infection or acidified ethanol gastric lesion.
Anti-osteoporosis effect
Osteoporosis, a major skeletal disease associated with
aging, has a number of subtypes, including senile osteoporosis
and postmenopausal or menopause-related osteoporosis
(Pietschmann et al. 2009). Osteoporosis affects great numb-
ers of individuals of both sexes and all races. Its prevalence
increases with age, and it has been estimated that more than
ten million Americans have osteoporosis and an additional
Fig. 4 Image analysis of gastric lesion. Rats fed yogurt, soy–skim
milk and fermented soy–skim milk for 4 weeks after pylorus ligation
combined with acidified ethanol induced acute gastric lesions of gastric
mucosa (left); the same images after optimised background subtraction
by ImageJ software (right) (Liu et al. 2009)
910 Appl Microbiol Biotechnol (2012) 93:903–916
33.6 million have low bone density of the hip (NOF 2010).
Loss of oestrogen seems to be the most important mecha-
nism in the development of osteoporosis. The use of
ovariectomised (OVX) rat or mice models, a well-
established and reproducible method of stimulating the
postmenopausal condition, has been found to be effective
in mimicking postmenopausal cancellous bone loss
(Egermann et al. 2005).
In a previous study, L. paracasei subsp. paracasei NTU
101 and L. plantarum NTU 102 were used as starter to
ferment soy–skim milk (NTU 101F and NTU 102F) and
then used as a nutritional supplement for 8 weeks in OVX
mice (Chiang and Pan 2011). The results showed that soy–
skim milk fermented with lactobacilli can increase the content
of aglycone isoflavones, soluble calcium and vitamin D3. The
trabecular bone volumes and trabecular number of the distal
femur in mice fed NTU 101F increased by factors of 1.48
and 1.74, respectively, relative to the OVX group. The 3D
reconstructions of micro-CT imaging and SEM images (×80
and ×130) of the endosteal surfaces of the femur metaphysis
at the ultrastructural level are shown in Fig. 5. The growth
plate in sham group was thicker than that in the other OVX
groups and showed that the sham mice were still growing.
The images of trabecular bone in the sham and OVX+NTU
101F groups indicate significantly greater thickness and
more plate formation than the images of the OVX group in
thinner rod form. The bone network density and thickness of
the distal metaphyseal trabecular bone in mice fed NTU
101F was significantly greater than that of the OVX mice.
Physiological phenomena associated with aging include
post-maturation processes, diminished homeostatic capacity,
reduced responsiveness to stimuli (Candore et al. 2008),
impaired memory acquisition, decreased immune responses,
increased peroxidation in vivo and loss of bone density
(Hayflick 2007; Candore et al. 2006). Chiang et al. (2011a)
also used lactobacilli-fermented soy–skim milk as a nutri-
tional supplement for 6 weeks to investigate its anti-
osteoporosis effect in 13-month-old female BALB/c (aging)
mice. In particular, the content of polysaccharides and pep-
tides of the NTU 101-fermented milk was the highest
among the groups (4.5 and 335.2 mg/g, respectively). The
trabecular bone volumes in mice fed NTU 101F increased
by a factor of 3.48 relative to controls. The network density
and thickness of distal metaphyseal trabecular bone in mice
fed NTU 101F milk was significantly higher than those in
the control mice. Moreover, the NTU 101F group had the
largest resting area ratio (84.5±4.5%) and the smallest
resorbing area (12.1±4.2%) when compared with the other
groups in Fig. 6. It was not possible to produce data for the
forming area for all aging mice as a result of the bone
remodelling rate and the decrease in bone mass with in-
creased age. The combined results of the OVX and aging
models suggest that dietary supplementation with NTU-101
fermented soy–skim milk can attenuate bone loss in mice
and possibly lower the risk of osteopenia or osteoporosis
(Chiang et al. 2011a).
The effect of long-term feeding of milk fermented
with L. helveticus on bone in growing rats was evaluated in
SHR rats (Narva et al. 2004). The bone mineral content and
bone mineral density related to the weight of the rats were
the highest after feeding with the L. helveticus fermented
milk, which contained more amounts of the IPP and VPP
peptides. Compared with the results of NTU 101F, it
showed that the fermentation process would enhance the
production of bioactive components and reveal the
anti-osteoporosis activity. Further studies are needed to
confirm and clarify the mechanism of lactobacilli-fermented
products.
Table 1 Effects of gastric lesion index in rats
Group Gastric lesion index
Lesion area (mm2) Total mucosal area (mm2) Lesion index
Control 99.01±18.43a 977.99±65.14a 1.01±0.18a
Yogurt 70.02±12.14ab 991.75±40.01a 0.70±0.12ab
Soy–skim milk 98.95±6.52a 1,010.33±46.62a 0.99±0.06a
101-8 84.83±12.47ab 1,054.08±43.85a 0.80±0.11ab
101-9 53.26±8.13b 993.42±45.77a 0.55±0.09b
102-8 72.89±13.36ab 998.60±39.74a 0.72±0.12ab
102-9 79.33±15.98ab 1,098.40±26.40a 0.66±0.14ab
Data are presented as mean (SEM) (n08); numbers with different letters within the same column are significantly different (p<0.05) (Liu et al.
2009)
Control normal diet, Yogurt commercial yogurt diet, Soy–skim milk nonfermented soy–skim milk, 101-8 108 CFU/day of soy–skim milk fermented
by L. paracasei subsp. paracasei NTU 101, 101-9 109 CFU/day of soy–skim milk fermented by L. paracasei subsp. paracasei NTU 101, 102-
8 108 CFU/day of soy–skim milk fermented by L. plantarum NTU 102; 102-9 109 CFU/day of soy–skim milk fermented by L. plantarum NTU 102
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Prevention of fat accumulation
Obesity is becoming a global epidemic in both children and
adults and is associated with morbidity due to CVDs, type II
diabetes, hypertension, metabolic syndrome and certain can-
cers (Poirier et al. 2006). These forms of obesity have two
important characteristics: increased accumulation of adipose
tissue and secretion of pathogenetic products from enlarged
fat cells (Bray 2004). The prevalence of obesity was 32.2%
among adult men and 35.5% among adult women from
2007 to 2008 in the USA. Increases in the outcomes of
obesity have previously been observed and exceeding 30%
in most sex and age groups (Flegal et al. 2010).
The composition of the microbial community is
inherited from mothers and is similar at the division
level in mice and humans. In obese mice vs. lean mice,
the abundance of Bacteroidetes decreases to 50% and
indicates that obesity affects the diversity of the gut
microbiota (Ley et al. 2005). Cani and Delzenne (2009)
hypothesised that relationships between the colon and the
regulation of energy metabolism are influenced by calories
ingested, synthesis of gut peptides and fat storage.
Moreover, the development of obesity and metabolic
disorders as a result of a high-fat diet may be associated
with an imbalance in the innate immune system, develop-
ment of metabolic endotoxemia and atherogenic markers in
subjects (Cani and Delzenne 2009).
Many recent studies have focused on the anti-obesity
effects of LAB (mainly the bifidobacteria and Lactobacillus
strains). Choi et al. (2007) indicated that oral administration
of Bifidobacterium breve-fermented isoflavone aglycones
effectively suppresses absorption of excessive lipid into
the body and inhibits adipocyte differentiation in 3T3-L1
cells in a dose-dependent manner. Mice fed a high-fat diet
supplemented with B. breve B-3 exhibit dose-dependent
suppression of accumulation of epididymal fat and
SHAM
OVX + NTU 101F OVX + NTU 102F OVX + NFSM
OVX OVX + FOS
(A) SHAM OVX OVX + FOS
OVX + NTU 101F OVX + NTU 102F OVX + NFSM
(B)
SHAM OVX + FOS
OVX + NTU 102F
OVX
OVX + NTU 101F OVX + NFSM
(C)
Fig. 5 Microstructural properties of the distal femoral metaphyseal
trabecular bone in C57BL/6J female ovariectomised mice after 8 weeks
of oral administration of either L. paracasei subsp. paracasei NTU 101
or L. plantarum NTU 102-fermented and nonfermented soy–skim
milk. a Three-dimensional tomographic rendering of a mouse femur
revealing the complexity of the bone structure (images of the distal
femoral metaphysis trabecular bone in 1.5-mm-thick images; the left-
hand image shows the side view and the right-hand image the top
view); b Electron microphotographs of the endosteal surface in the
femoral metaphysis of OVX C57BL/6J mice at ×80; c ×130. Scale bar:
b 1 mm; c 500 μm. Red arrow represents the cylindrical rod form
trabecular bone, and the blue arrow represents the parallel plate form
trabecular bone. (Chiang and Pan 2011)
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upregulation of genes related to fat metabolism and insulin
sensitivity in the gut and epididymal fat tissue (Kondo et al.
2010). Kim et al. (2008b) showed that the SoyproTM (a new
brand of soymilk) fermented by Leuconostoc citreum and L.
plantarum decreases levels of LDL-C in SD rats and inhibits
the differentiation of 3T3-L1 adipocytes (Kim et al. 2008a,
b). L. plantarum strain no. 14 was also reported to decrease
the mean adipocyte size and white adipose tissue weight and
to decrease the serum total cholesterol and leptin
concentrations (Takemura et al. 2010). The anti-obesity
effects of L. gasseri SBT2055 cause lowering of abdominal
adiposity, body weight, body mass index and waist and hip
circumference. These observations suggest that this strain
exerts a beneficial influence on metabolic disorders
(Kadooka et al. 2010). In contrast, L. rhamnosus PL60
was found to only reduce the body weight and white (epi-
didymal and perirenal) adipose tissue due to production of
t10, c12-conjugated linoleic acid (Lee et al. 2006).
Fig. 6 Measurements of
endosteal surface of femoral
diaphysis in aging BALB/c
mice. a Scanning electron
microphotographs of the
endosteal surface in the femoral
diaphysis in aging BALB/c
mice. b Percentage of bone
surface types on the endosteal
surface of the femoral diaphysis.
Scale bar 200 μm. R resting
area, asterisk resorbing area.
Data are expressed as mean±SD
(n05). Means with different
letters compared within the
resorbing area or resting area
were significantly different
(p<0.01) (Chiang et al. 2011a)
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The flavonoid genistein was found to inhibit proliferation
of preconfluent preadipocytes in a time- and dose-dependent
manner and to regulate body fat in terms of preadipocyte
replication, differentiation and lipolysis (Harmon and Harp
2001). Daidzein is another flavonoid that can significantly
reduce body fat weight and ameliorate hyperlipidemia. This
flavonoid also inhibits the activity of pancreatic and lipo-
protein lipase and the differentiation of rat preadipocytes
(Guo et al. 2009).
In a previous study, Lo (2011) reported that the L. para-
casei subsp. paracasei NTU 101 (NTU 101) strain and its
fermented soy–skim milk supernatant (SM 101) adminis-
tered as supplements for 5 weeks produce anti-obesity
effects in rats maintained on a high-fat diet. A high-fat diet
supplemented with NTU 101 and SM101 can significantly
decrease feed efficiency, body weight and body fat pad
weight of rats. SM101 causes decreases in feed efficiency,
body weight and body fat pad weight of 53.2%, 49.7% and
55.9%, respectively. Moreover, NTU 101 and SM101 also
reduce the average radius of adipocytes and increase the
number of small adipocytes. These results reveal that NTU
101 and SM 101 have the ability to prevent the body fat
accumulation. The bioactive compounds in NTU 101 and
SM 101 that possess the prevention effect in fat accumula-
tion may be the aglycone isoflavones.
Regardless of the cell line system or diet-induced obesity
animal model used, these results were showed that LAB
inhibited the adipocyte differentiation and reduced the body
weight gain, white adipose tissue weight and mean adipo-
cyte size.
Conclusion
Many pioneering scientific studies on beneficial effects of L.
paracasei subsp. paracasei NTU 101 and its fermented
products have been conducted by different methodologies
and test system trials. The evidences on this probiotic strain
are performed to ameliorate hypercholesterolemia, hyper-
tension, allergy, gastric lesion, osteoporosis and obesity.
The production of Lactobacillus-fermented products is im-
proved to enhance the contents of GABA, biogenic peptides
and aglycone isoflavones. Therefore, more data will be
forthcoming to explore its bioactive components and their
therapeutic effects in the near future.
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